Massachusetts S783 aims to promote transparency and prevent price gouging of pharmaceutical drug prices.

Massachusetts S783 seeks to enhance transparency and prevent price gouging in pharmaceutical drug pricing. The bill mandates pharmaceutical manufacturing companies to provide early notice to the commission for new molecular entities, generic drugs, and biosimilar drugs. It requires manufacturers to submit access improvement plans if their pricing substantially exceeds the commission's proposed value. The commission can impose penalties for non-compliance and requires manufacturers to report on their pricing strategies.

Massachusetts S783 aims to promote transparency and prevent price gouging of pharmaceutical drug prices.

Massachusetts S783 seeks to enhance transparency and prevent price gouging in pharmaceutical drug pricing. The bill mandates pharmaceutical manufacturing companies to provide early notice to the commission for new molecular entities, generic drugs, and biosimilar drugs. It requires manufacturers to submit access improvement plans if their pricing substantially exceeds the commission's proposed value. The commission can impose penalties for non-compliance and requires manufacturers to report on their pricing strategies.